Re: Wells et  al.: Aflibercept, Bevacizumab, or Ranibizumab for diabetic macular edema: two year results from a comparative effectiveness randomized clinical trial (Ophthalmology. 2016;123:1351-1359)

The Diabetic Retinopathy Clinical Research Network (DRCR.net) has made useful observations regarding diabetic retinopathy, including their most recent manuscript.1 However, I have questions about their classification of and conclusions about diabetic macular edema (DME). In an earlier manuscript, DRCR.net concluded that “little evidence exists that characteristics of DME described by the terms focal and diffuse help to explain variation in visual acuity or response to treatment” and that “it is unresolved whether a concept of focal and diffuse DME will prove clinically useful despite frequent usage of the ter ms when describing management of DME.
Source: Ophthalmology - Category: Opthalmology Authors: Tags: Correspondence Source Type: research